Sirnaomics to Start Clinical Trials of RNAi Candidate in China

Sirnaomics, a Maryland-Suzhou RNAi company, will add a China Phase IIb trial for its lead drug to the US trial, already underway. The company will test STP705, a siRNA (small interfering RNA) candidate that inhibits TGF-β1 and COX-2 gene expression in patients with skin squamous cell carcinoma (in situ). Sirnaomics uses its polypeptide nanoparticle (PNP)-enhanced technology to deliver the drug. The trial will enroll 100 adult patients with isSCC in five to seven clinical sites in the US and  China . STP705 is also approved for testing in cholangiocarcinoma, non-melanoma skin cancer and hypertrophic scar. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.